Ultragenyx Pharmaceutical Inc Q4 Loss decreases, beats estimates

(RTTNews) - Ultragenyx Pharmaceutical Inc (RARE) revealed Loss for fourth quarter that decreased from the same period last year and beat the Street estimates.

The company's earnings came in at -$123.2 million, or -$1.52 per share. This compares with -$151.8 million, or -$2.16 per share, in last year's fourth quarter.

Analysts on average had expected the company to earn -$1.62 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 23.3% to $127.4 million from $103.3 million last year.

Ultragenyx Pharmaceutical Inc earnings at a glance (GAAP) :

-Earnings (Q4): -$123.2 Mln. vs. -$151.8 Mln. last year. -EPS (Q4): -$1.52 vs. -$2.16 last year. -Analyst Estimates: -$1.62 -Revenue (Q4): $127.4 Mln vs. $103.3 Mln last year.